Is Raptor Pharmaceuticals Ready to Roar?

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Raptor Pharmaceuticals (Nasdaq: RPTP  ) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Raptor and see what CAPS investors are saying about the stock right now.

Raptor facts


Novato, Calif.

Market Cap

$232.9 million



Trailing-12-Month EBITDA

($36 million)


Co-Founder/CEO Dr. Christopher Starr
CFO Georgia Erbez

Return on Capital (average, past 3 years)



$43.1 million / $23.4 thousand


AstraZeneca (NYSE: AZN  )
Endo Health Solutions (Nasdaq: ENDP  )
Pfizer (NYSE: PFE  )

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 50 members who have rated Raptor believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star zzlangerhans, highlighted Raptor as a strictly short-term opportunity:

I'm a long-term skeptic on Raptor, but I believe the stock is due for a turn-around before the DR Cysteamine PDUFA for cystinosis on January 30. Will convenience and a reduction in side effects convince insurers to pay 10-20 times as much as they pay now for the current therapy? I doubt it, and I don't think traders buying into the PDUFA will stick around to find out. Far-fetched use of the same compound for Huntington's disease and NASH is still in pie-in-the-sky stage and won't provide much lift until late 2013. This is a quick ditch if I have a positive score going into the PDUFA.

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a perfect five-star rating, Raptor may not be your top choice.

We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 19, 2012, at 8:20 PM, carletones wrote:

    RPTP weak. ATM will be in full effect Q1 2013 and FDA may approve, but cost...yikes.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2116888, ~/Articles/ArticleHandler.aspx, 10/21/2016 2:28:16 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,135.10 -27.25 -0.15%
S&P 500 2,139.73 -1.61 -0.08%
NASD 5,251.56 9.72 0.19%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 2:12 PM
RPTP $9.00 Down +0.00 +0.00%
Raptor Pharmaceuti… CAPS Rating: ***
AZN $30.76 Down -0.24 -0.77%
AstraZeneca CAPS Rating: ****
ENDP $20.82 Up +0.29 +1.41%
Endo International CAPS Rating: ****
PFE $32.25 Down -0.29 -0.89%
Pfizer CAPS Rating: ****